Ajit Naidu, MD
Cardiovascular Disease · Florence, ALNPI 1912904913
Payments from drug & device makers
What this record shows
This record is dominated by other: $63,700 of the $66,093 with a category attached, or 96.4%. Convatec Inc. accounts for 96.4% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $63,897, more than ten times the $1,013 reported in 2019. Among cardiovascular disease clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 90 payments — averaging $734.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Convatec Inc.$64K
- Boston Scientific$915
- Boehringer Ingelheim$324
- Merck$190
- Venclose Inc.$156
- Medtronic$143
- plus $624 from 14 others
What the payments were for
- Travel & lodging$1310%
- Food & beverage$2,2413%
- Education$220%
- Other$63,70096%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Convatec Inc. | 4 | $63,740 |
| Boston Scientific | 16 | $915 |
| Boehringer Ingelheim | 14 | $324 |
| Merck | 12 | $190 |
| Venclose Inc. | 4 | $156 |
| Medtronic(2 entities) | 9 | $143 |
| Bard Peripheral Vascular, Inc. | 5 | $119 |
| Revance Therapeutics, Inc. | 1 | $98 |
| Novo Nordisk | 4 | $73 |
| Pfizer | 5 | $63 |
| Amgen | 4 | $56 |
| Biocompatibles, Inc. | 2 | $53 |
| Philips North America LLC | 2 | $33 |
| Angiodynamics, Inc. | 2 | $30 |
| Abbott | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Organogenesis Inc. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Triad Life Sciences Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- InnovaMatrix AC$63,700
- ELUVIA$236
How this compares
$66,093 in reported general payments places this provider in the 95th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 73 | $64,144 |
| EliquisApixaban | 46 | $40,582 |
| XareltoRivaroxaban | 12 | $16,545 |
| Metoprolol Succinate | 50 | $845 |
| Ranolazine ErRanolazine | 13 | $572 |
| ClopidogrelClopidogrel Bisulfate | 48 | $569 |
| Cilostazol | 22 | $468 |
| Ropinirole Hcl | 30 | $457 |
| Atorvastatin Calcium | 28 | $447 |
| Amlodipine Besylate | 64 | $348 |
| Gabapentin | 30 | $320 |
| Carvedilol | 16 | $124 |
| Omeprazole | 14 | $120 |
| Rosuvastatin Calcium | 13 | $119 |
| Losartan Potassium | 13 | $118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $324 | $64,14473 claims |
| PfizerEliquis | $63 | $40,58246 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Florence
- Ram SapkotaFlorence$11K
- Sean RhulandFlorence$9K
- Dennis ThomasMobile$894K
- David FienoAlabaster$421K
- Vikram AroraBirmingham$271K
- Jason ThompsonBirmingham$248K
- Michael WilenskyBirmingham$241K
- Mustafa AhmedBirmingham$218K
- Frederick GaskinBirmingham$115K
- Pankaj AroraBirmingham$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.